In a recent report, Kotak Securities said that most enterprises are focused on cost reduction; moreover, trends do not indicate the possibility of recovery in discretionary spending in 1HCY24

Read More

​ In a recent report, Kotak Securities said that most enterprises are focused on cost reduction; moreover, trends do not indicate the possibility of recovery in discretionary spending in 1HCY24 In a recent report, Kotak Securities said that most enterprises are focused on cost reduction; moreover, trends do not indicate the possibility of recovery in discretionary spending in 1HCY24  Moneycontrol Latest News Read More  

In a recent report, Kotak Securities said that most enterprises are focused on cost reduction; moreover, trends do not indicate the possibility of recovery in discretionary spending in 1HCY24

MIC has become a wholly-owned subsidiary of the company. MIC Insurance Web Aggregator is an IRDAI registered insurance web aggregator.

Read More

​ MIC has become a wholly-owned subsidiary of the company. MIC Insurance Web Aggregator is an IRDAI registered insurance web aggregator. MIC has become a wholly-owned subsidiary of the company. MIC Insurance Web Aggregator is an IRDAI registered insurance web aggregator.  Moneycontrol Latest News Read More  

MIC has become a wholly-owned subsidiary of the company. MIC Insurance Web Aggregator is an IRDAI registered insurance web aggregator.

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated December 08, 2023.

Read More

​ Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated December 08, 2023. Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated December 08, 2023.  Moneycontrol Latest News Read More  

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated December 08, 2023.

On November 23, Moneycontrol citing sources reported that bank will raise Rs 1,000 crore in early December.

Read More

​ On November 23, Moneycontrol citing sources reported that bank will raise Rs 1,000 crore in early December. On November 23, Moneycontrol citing sources reported that bank will raise Rs 1,000 crore in early December.  Moneycontrol Latest News Read More  

On November 23, Moneycontrol citing sources reported that bank will raise Rs 1,000 crore in early December.

Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter

Read More

​ Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter  Moneycontrol Latest News Read More  

Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter

Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter

Read More

​ Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter  Moneycontrol Latest News Read More  

Antique Broking estimates the Bachupally unit contributes nearly 30 percent to Dr Reddy#39;s US revenue and adverse observations could lead to a warning letter

In between Los Angeles screenings at the AFI Fest and 2024 Academy Awards, Amanda Nell Eu#39;s debut horror feature #39;Tiger Stripes#39;, about the monstrosity of puberty, the first Malaysian film ever to win the Cannes Grand Jury prize, screens at the ongoing 2023 International Film Festival of Kerala.

Read More

​ In between Los Angeles screenings at the AFI Fest and 2024 Academy Awards, Amanda Nell Eu#39;s debut horror feature #39;Tiger Stripes#39;, about the monstrosity of puberty, the first Malaysian film ever to win the Cannes Grand Jury prize, screens at the ongoing 2023 International Film Festival of Kerala. In between Los Angeles screenings at the AFI Fest and 2024 Academy Awards, Amanda Nell Eu#39;s debut horror feature #39;Tiger Stripes#39;, about the monstrosity of puberty, the first Malaysian film ever to win the Cannes Grand Jury prize, screens at the ongoing 2023 International Film Festival of Kerala.  Moneycontrol Latest News Read More  

In between Los Angeles screenings at the AFI Fest and 2024 Academy Awards, Amanda Nell Eu#39;s debut horror feature #39;Tiger Stripes#39;, about the monstrosity of puberty, the first Malaysian film ever to win the Cannes Grand Jury prize, screens at the ongoing 2023 International Film Festival of Kerala.

In between LA screenings at AFI Fest and 2024 Academy Awards, #39;Tiger Stripes#39;, Amanda Nell Eu#39;s Cannes Grand Jury prize-winning debut Malaysian horror feature about the monstrosity of puberty, screens at 2023 International Film Festival of Kerala.

Read More

​ In between LA screenings at AFI Fest and 2024 Academy Awards, #39;Tiger Stripes#39;, Amanda Nell Eu#39;s Cannes Grand Jury prize-winning debut Malaysian horror feature about the monstrosity of puberty, screens at 2023 International Film Festival of Kerala. In between LA screenings at AFI Fest and 2024 Academy Awards, #39;Tiger Stripes#39;, Amanda Nell Eu#39;s Cannes Grand Jury prize-winning debut Malaysian horror feature about the monstrosity of puberty, screens at 2023 International Film Festival of Kerala.  Moneycontrol Latest News Read More  

In between LA screenings at AFI Fest and 2024 Academy Awards, #39;Tiger Stripes#39;, Amanda Nell Eu#39;s Cannes Grand Jury prize-winning debut Malaysian horror feature about the monstrosity of puberty, screens at 2023 International Film Festival of Kerala.

Urban India to contribute to 75 percent of GDP by 2030. Future proofing cities from climate events such as cyclone Michaung is imperative

Read More

​ Urban India to contribute to 75 percent of GDP by 2030. Future proofing cities from climate events such as cyclone Michaung is imperative Urban India to contribute to 75 percent of GDP by 2030. Future proofing cities from climate events such as cyclone Michaung is imperative  Moneycontrol Latest News Read More  

Urban India to contribute to 75 percent of GDP by 2030. Future proofing cities from climate events such as cyclone Michaung is imperative

Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.

Read More

​ Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing. Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.  Moneycontrol Latest News Read More  

Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.